92 related articles for article (PubMed ID: 12684403)
21. An EORTC phase I study of Bortezomib in combination with oxaliplatin, leucovorin and 5-fluorouracil in patients with advanced colorectal cancer.
Caponigro F; Lacombe D; Twelves C; Bauer J; Govaerts AS; Marréaud S; Milano A; Anthoney A
Eur J Cancer; 2009 Jan; 45(1):48-55. PubMed ID: 18809314
[TBL] [Abstract][Full Text] [Related]
22. Phase I/II study of iodine 125-labeled monoclonal antibody A33 in patients with advanced colon cancer.
Welt S; Scott AM; Divgi CR; Kemeny NE; Finn RD; Daghighian F; Germain JS; Richards EC; Larson SM; Old LJ
J Clin Oncol; 1996 Jun; 14(6):1787-97. PubMed ID: 8656247
[TBL] [Abstract][Full Text] [Related]
23. Serological analysis of human anti-human antibody responses in colon cancer patients treated with repeated doses of humanized monoclonal antibody A33.
Ritter G; Cohen LS; Williams C; Richards EC; Old LJ; Welt S
Cancer Res; 2001 Sep; 61(18):6851-9. PubMed ID: 11559561
[TBL] [Abstract][Full Text] [Related]
24. Safety, pharmacokinetics and pharmacodynamics of the anti-A33 fully-human monoclonal antibody, KRN330, in patients with advanced colorectal cancer.
Infante JR; Bendell JC; Goff LW; Jones SF; Chan E; Sudo T; Burris HA; Berlin JD
Eur J Cancer; 2013 Apr; 49(6):1169-75. PubMed ID: 23294608
[TBL] [Abstract][Full Text] [Related]
25. Phase I/II study of G17-DT, an anti-gastrin immunogen, in advanced colorectal cancer.
Smith AM; Justin T; Michaeli D; Watson SA
Clin Cancer Res; 2000 Dec; 6(12):4719-24. PubMed ID: 11156225
[TBL] [Abstract][Full Text] [Related]
26. Immunotherapy for recurrent colorectal cancers with human monoclonal antibody SK-1.
Koda K; Glassy MC; McKnight ME; Yasutomi J; Saito N; Dan M; Nakajima N
Anticancer Res; 2001; 21(1B):621-7. PubMed ID: 11299816
[TBL] [Abstract][Full Text] [Related]
27. Phase II study of dual 131I-labeled monoclonal antibody therapy with interferon in patients with metastatic colorectal cancer.
Meredith RF; Khazaeli MB; Plott WE; Grizzle WE; Liu T; Schlom J; Russell CD; Wheeler RH; LoBuglio AF
Clin Cancer Res; 1996 Nov; 2(11):1811-8. PubMed ID: 9816134
[TBL] [Abstract][Full Text] [Related]
28. A phase I radioimmunolocalization trial of humanized monoclonal antibody huA33 in patients with gastric carcinoma.
Sakamoto J; Oriuchi N; Mochiki E; Asao T; Scott AM; Hoffman EW; Jungbluth AA; Matsui T; Lee FT; Papenfuss A; Kuwano H; Takahashi T; Endo K; Old LJ
Cancer Sci; 2006 Nov; 97(11):1248-54. PubMed ID: 17034367
[TBL] [Abstract][Full Text] [Related]
29. Antibody-directed enzyme prodrug therapy: efficacy and mechanism of action in colorectal carcinoma.
Napier MP; Sharma SK; Springer CJ; Bagshawe KD; Green AJ; Martin J; Stribbling SM; Cushen N; O'Malley D; Begent RH
Clin Cancer Res; 2000 Mar; 6(3):765-72. PubMed ID: 10741695
[TBL] [Abstract][Full Text] [Related]
30. 124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.
O'Donoghue JA; Smith-Jones PM; Humm JL; Ruan S; Pryma DA; Jungbluth AA; Divgi CR; Carrasquillo JA; Pandit-Taskar N; Fong Y; Strong VE; Kemeny NE; Old LJ; Larson SM
J Nucl Med; 2011 Dec; 52(12):1878-85. PubMed ID: 22068895
[TBL] [Abstract][Full Text] [Related]
31. (124)I-huA33 antibody PET of colorectal cancer.
Carrasquillo JA; Pandit-Taskar N; O'Donoghue JA; Humm JL; Zanzonico P; Smith-Jones PM; Divgi CR; Pryma DA; Ruan S; Kemeny NE; Fong Y; Wong D; Jaggi JS; Scheinberg DA; Gonen M; Panageas KS; Ritter G; Jungbluth AA; Old LJ; Larson SM
J Nucl Med; 2011 Aug; 52(8):1173-80. PubMed ID: 21764796
[TBL] [Abstract][Full Text] [Related]
32. Monoclonal antibody treatment of colorectal cancer.
Pullyblank AM; Monson JR
Br J Surg; 1997 Nov; 84(11):1511-7. PubMed ID: 9393269
[TBL] [Abstract][Full Text] [Related]
33. The diagnostic and therapeutic use of monoclonal antibodies in colorectal cancer.
Kaplan EH
Hematol Oncol Clin North Am; 1989 Mar; 3(1):125-34. PubMed ID: 2645269
[TBL] [Abstract][Full Text] [Related]
34. Monoclonal antibodies (MAb 17-1A) for the treatment of patients with metastatic colorectal carcinomas.
Mellstedt H; Frödin JE; Masucci G; Lindemalm C; Wedelin C; Christensson B; Shetye J; Biberfeld P; Lefvert AK; Pihlstedt P
Acta Chir Scand Suppl; 1989; 549():63-70. PubMed ID: 2929214
[No Abstract] [Full Text] [Related]
35. Phase I clinical trial of drug-monoclonal antibody conjugates in patients with advanced colorectal carcinoma: a preliminary report.
Tjandra JJ; Pietersz GA; Teh JG; Cuthbertson AM; Sullivan JR; Penfold C; McKenzie IF; Smyth M
Surgery; 1989 Sep; 106(3):533-45. PubMed ID: 2788931
[TBL] [Abstract][Full Text] [Related]
36. Heterogeneous expression of A33 in colorectal cancer: possible explanation for A33 antibody treatment failure.
Baptistella AR; Salles Dias MV; Aguiar S; Begnami MD; Martins VR
Anticancer Drugs; 2016 Sep; 27(8):734-7. PubMed ID: 27272411
[TBL] [Abstract][Full Text] [Related]
37. Quantitative intratumoural microdistribution and kinetics of (131)I-huA33 antibody in patients with colorectal carcinoma.
Ciprotti M; Chong G; Gan HK; Chan A; Murone C; MacGregor D; Lee FT; Johns TG; Heath JK; Ernst M; Burgess AW; Scott AM
EJNMMI Res; 2014; 4():22. PubMed ID: 24995151
[TBL] [Abstract][Full Text] [Related]
38. [Current view and possibilities of chemotherapy sensitivity and resistance assays and metabolic enzyme analysis in individualized chemotherapy for the patients with colorectal cancer].
Ishii Y; Hasegawa H; Endo T; Ochiai H; Kitagawa Y
Nihon Rinsho; 2011 Apr; 69 Suppl 3():487-93. PubMed ID: 22214009
[No Abstract] [Full Text] [Related]
39. Monoclonal antibody-functionalized multilayered particles: targeting cancer cells in the presence of protein coronas.
Dai Q; Yan Y; Ang CS; Kempe K; Kamphuis MM; Dodds SJ; Caruso F
ACS Nano; 2015 Mar; 9(3):2876-85. PubMed ID: 25712076
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
